Literature DB >> 23560804

Dibenzodiazepine derivative quetiapine- and olanzapine-induced chronic interstitial nephritis.

Liyu He1, Youming Peng, Xiao Fu, Xiaogang Chen, Hong Liu.   

Abstract

The dibenzodiazepine derivative is a so-called "atypical" or second-generation antipsychotic that is widely regarded as one of the most effective drug treatments for schizophrenia and depression. Quetiapine and olanzapine are novel atypical antipsychotic agents that possess much improved tolerability. To the best of our knowledge, FDA has reported three cases of olanzapine-induced interstitial nephritis. Yet there have been no known clinical reports that associate quetiapine treatment with chronic interstitial nephritis (CIN). Here, we report the occurrence of CIN in the presence of edema during quetiapine and olanzapine therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560804     DOI: 10.3109/0886022X.2013.780615

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  4 in total

1.  A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.

Authors:  Yawen Jiang; Jeffrey S McCombs; Susie H Park
Journal:  CNS Drugs       Date:  2017-04       Impact factor: 5.749

2.  Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study.

Authors:  Chen-Yi Liao; Chi-Hsiang Chung; Kuo-Cheng Lu; Cheng-Yi Cheng; Sung-Sen Yang; Wu-Chien Chien; Chia-Chao Wu
Journal:  Front Pharmacol       Date:  2021-01-25       Impact factor: 5.810

3.  The Effects of Use of Long-Term Second-Generation Antipsychotics on Liver and Kidney Function: A Prospective Study.

Authors:  Evangelia Papatriantafyllou; Dimitris Efthymiou; Maria Markopoulou; Efthymia-Maria Sakellariou; Emilia Vassilopoulou
Journal:  Diseases       Date:  2022-07-22

4.  Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study.

Authors:  Mikkel Højlund; Lars Christian Lund; Jonas Leander Emming Herping; Maija Bruun Haastrup; Per Damkier; Daniel Pilsgaard Henriksen
Journal:  BMJ Open       Date:  2020-08-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.